Literature DB >> 18362907

The CD4+CD26- T-cell population in classical Hodgkin's lymphoma displays a distinctive regulatory T-cell profile.

Yue Ma1, Lydia Visser, Tjasso Blokzijl, Geert Harms, Cigdem Atayar, Sibrand Poppema, Anke van den Berg.   

Abstract

Little is known about the gene expression profile and significance of the rosetting CD4+CD26- T cells in classical Hodgkin's lymphoma (cHL). To characterize these T cells, CD4+CD26- and CD4+CD26+ T-cell populations were sorted from lymph node (LN) cell suspensions from nodular sclerosis HL (NSHL) and reactive LNs. mRNA profiles of stimulated and resting cell subsets were evaluated with quantitative RT-PCR for 46 genes. We observed a higher percentage of CD4+CD26- T cells in NSHL than in reactive LNs. The resting CD4+CD26- T cells in NSHL showed higher mRNA levels of CD25, CTLA4, OX40 and CCR4 compared with in LNs, supporting a regulatory T-cell (Treg) type, and this was validated by immunohistochemistry. Moreover, these cells showed low or no expression of the Th1- or Th2-related cytokines IL-2, IFN-gamma, IL-13, IL-12B, IL-4, and IL-5, and the chemoattractant receptor CRTH2. Besides Tregs, Th17 cells may exist in NSHL based on the significantly higher IL-17 mRNA level for both T-cell populations in NSHL. Upon stimulation in vitro, lack of upregulation of mRNA levels of most cytokine genes indicated an anergic character for the CD4+CD26- T-cell subset. Anergy fits with the Treg profile of these cells, probably explaining the immunosuppressive mechanism involved in NSHL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18362907     DOI: 10.1038/labinvest.2008.24

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  15 in total

Review 1.  The immunological contribution of NF-κB within the tumor microenvironment: a potential protective role of zinc as an anti-tumor agent.

Authors:  Bin Bao; Archana Thakur; Yiwei Li; Aamir Ahmad; Asfar S Azmi; Sanjeev Banerjee; Dejuan Kong; Shadan Ali; Lawrence G Lum; Fazlul H Sarkar
Journal:  Biochim Biophys Acta       Date:  2011-11-29

2.  New developments in the pathology of malignant lymphoma: a review of the literature published from May to July 2008.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2008-09       Impact factor: 0.196

3.  Flow cytometric detection of the classical hodgkin lymphoma: clinical and research applications.

Authors:  Mikhail Roshal; Brent L Wood; Jonathan R Fromm
Journal:  Adv Hematol       Date:  2010-11-28

4.  T-Cell Traffic Jam in Hodgkin's Lymphoma: Pathogenetic and Therapeutic Implications.

Authors:  Claudio Fozza; Maurizio Longinotti
Journal:  Adv Hematol       Date:  2010-10-12

Review 5.  The role of T cells in the microenvironment of Hodgkin lymphoma.

Authors:  Frederik Wein; Ralf Küppers
Journal:  J Leukoc Biol       Date:  2015-08-28       Impact factor: 4.962

6.  Rare association of Hodgkin lymphoma, Graves' disease and myasthenia gravis complicated by post-radiation neurofibrosarcoma: coincidence or genetic susceptibility?

Authors:  Zsófia Simon; Zsuzsa Ress; József Toldi; Anita Trauninger; Zsófia Miltényi; Árpád Illés
Journal:  Int J Hematol       Date:  2009-04-21       Impact factor: 2.490

7.  Targeting the tumor niche to treat cancer.

Authors:  Sattva S Neelapu; Padmanee Sharma
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-08       Impact factor: 11.205

8.  The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein-Barr virus presence and location within the tumor.

Authors:  R Wu; A Sattarzadeh; B Rutgers; A Diepstra; A van den Berg; L Visser
Journal:  Blood Cancer J       Date:  2016-05-06       Impact factor: 11.037

9.  Expression of CD1d and presence of invariant NKT cells in classical Hodgkin lymphoma.

Authors:  Chuanhui Xu; Riemer de Vries; Lydia Visser; Arjan Diepstra; Stephan D Gadola; Sibrand Poppema; Anke van den Berg
Journal:  Am J Hematol       Date:  2010-07       Impact factor: 10.047

Review 10.  CD26 and Asthma: a Comprehensive Review.

Authors:  Juan J Nieto-Fontarigo; Francisco J González-Barcala; Esther San José; Pilar Arias; Montserrat Nogueira; Francisco J Salgado
Journal:  Clin Rev Allergy Immunol       Date:  2019-04       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.